GLP-1 작용제 - 당뇨병과 체중 감소를 돕고 심장병의 위험을 줄이는 것으로 나타난 약물 종류는 뇌를 보호할 수도 있다. 2b 상 시험...
“That could significantly improve patient convenience,” a Metsera official said. Metsera plans to initiate a phase 2b trial by the end of this year, aiming to present data in the first half of 2025. Metsera has also acquired six oral peptide candidates from D&D Pharmatech in 2023 and 202...